Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.58 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.57 |
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | CTSS | P25774 | 1/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.54 |
| ▸ | ITGAV | P06756 | 2/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
| ▸ | TGM2 | P21980 | 2/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7515531 | 1.00 | FOLH1 (0.58) | FOLH1SIRT2SIRT1CTSLCTSS | |
| SCHEMBL19658555 | 0.96 | FOLH1 (0.60) | FOLH1SIRT2SIRT1CTSLCTSS | |
| SCHEMBL26641195 | 0.96 | FOLH1 (0.60) | FOLH1SIRT2SIRT1CTSLCTSS | |
| SCHEMBL600823 | 0.96 | FOLH1 (0.60) | FOLH1SIRT2SIRT1CTSLCTSS | |
| SCHEMBL8387978 | 0.93 | FOLH1 (0.65) | FOLH1SIRT2SIRT1CTSLCTSS | |
| SCHEMBL10421088 | 0.93 | FOLH1 (0.62) | FOLH1SIRT2SIRT1CTSLCTSS | |
| SCHEMBL18405554 | 0.91 | CTSL (0.56) | SIRT2SIRT1CTSLCTSSCTSK | |
| SCHEMBL7520841 | 0.91 | CTSL (0.66) | CTSLCTSSCTSKTACR1 | |
| SCHEMBL1111208 | 0.91 | PPARA (0.55) | FOLH1SIRT2SIRT1CTSLCTSS | |
| SCHEMBL1111209 | 0.91 | PPARA (0.55) | FOLH1SIRT2SIRT1CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108884058-B | Macrocyclic broad spectrum antibiotics | 阿奇克斯制药公司 | 2022-04-29 | — | — | CN | disclosed |
| US-7312218-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB CO. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | HAN WEI | 2007-05-03 | — | — | US | disclosed |
| US-7169795-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-20040249205-A1 | Process for producing hydroxyamino acid derivative | MERCIAN CORPORATION (JP) | 2004-12-09 | — | — | US | disclosed |
| EP-0758328-B1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BTG INT LTD (GB) | 2003-07-16 | — | — | EP | disclosed |
| EP-0641800-B1 | Lactol derivatives as inhibitors of cathepsin L | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-01-16 | — | — | EP | disclosed |
| EP-1133478-A1 | NOVEL ACYLGUANIDINE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000031046-A1 | NOVEL ACYLGUANIDINE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2000-06-02 | — | — | WO | disclosed |
| US-5753660-A | Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1998-05-19 | — | — | US | disclosed |
| US-5747499-A | CYCLOPENTAQUINAZOLINE COMPOUNDS CYCLOPENTAQUINAZOLINE COMPOUNDS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1998-05-05 | — | — | US | disclosed |
| EP-0758328-A1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BTG INTERNATIONAL LIMITED (GB) | 1997-02-19 | — | — | EP | disclosed |
| US-5496834-A | PEPTIDE DERIVATIVES AS CATHEPSIN L INHIBITORS AND INHIBITORS OF BONE RESORPTION OR TREATMENT OF OSTEOPOROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-05 | — | — | US | disclosed |
| WO-1995030673-A1 | ANTI-CANCER COMPOUNDS CONTAINING CYCLOPENTAQUINAZOLINE RING | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-11-16 | — | — | WO | disclosed |
| EP-0641800-A1 | Lactol derivatives as inhibiters of cathepsin L | Takeda Chemical Industries, Ltd. (JP) | 1995-03-08 | — | — | EP | disclosed |
| WO-1994012163-A1 | 2-NITROARYL AND 2-CYANOARYL COMPOUNDS AS REGULATORS OF NITRIC OXIDE SYNTHASE | ABBOTT LABORATORIES (US) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249205-A1 | Process for producing hydroxyamino acid derivative | HAAO, HDGF, BCAT1 | FOLH1 666/4885SIRT2 2496/4885SIRT1 3633/4885 |
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | TFPI, F12, F5 | FOLH1 798/4885SIRT2 1162/4885SIRT1 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.